Compass Therapeutics (NASDAQ:CMPX) Stock Price Down 5.3% - Here's Why

Key Points

• Compass Therapeutics' stock price fell 5.3% to $4.04, with trading volume down 38% from its average, suggesting decreased investor interest.
• Despite the recent decline, brokerage analysts' ratings remain optimistic, with target prices ranging from $9.00 to $12.00 and an average rating of "Moderate Buy."
• The company reported a loss of $0.14 earnings per share in its latest quarterly earnings, missing analyst expectations of a $0.13 loss by a slight margin.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report)'s stock price was down 5.3% during mid-day trading on Monday . The company traded as low as $4.05 and last traded at $4.04. Approximately 876,925 shares traded hands during mid-day trading, a decline of 38% from the average daily volume of 1,422,210 shares. The stock had previously closed at $4.26.

Analyst Ratings Changes

A number of brokerages have weighed in on CMPX. Raymond James Financial upgraded shares of Compass Therapeutics to an "outperform" rating and set a $9.00 target price on the stock in a research report on Tuesday, July 1st. Compass Point set a $10.00 target price on shares of Compass Therapeutics in a report on Monday, October 6th. Guggenheim upped their price objective on shares of Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Tuesday, August 12th. Lifesci Capital began coverage on shares of Compass Therapeutics in a report on Monday, October 6th. They set an "outperform" rating and a $10.00 price objective on the stock. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Compass Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Compass Therapeutics has an average rating of "Moderate Buy" and an average target price of $13.10.

Compass Therapeutics Stock Down 4.9%

The firm's 50-day moving average price is $3.52 and its 200 day moving average price is $2.74. The company has a market capitalization of $560.03 million, a P/E ratio of -9.00 and a beta of 1.48.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). As a group, equities research analysts expect that Compass Therapeutics, Inc. will post -0.36 EPS for the current year.

Institutional Investors Weigh In On Compass Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its position in shares of Compass Therapeutics by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 243,565 shares of the company's stock valued at $463,000 after acquiring an additional 5,590 shares during the period. Apollon Wealth Management LLC bought a new position in shares of Compass Therapeutics during the 3rd quarter valued at approximately $35,000. Creative Planning bought a new position in shares of Compass Therapeutics during the 2nd quarter valued at approximately $30,000. Charles Schwab Investment Management Inc. grew its position in shares of Compass Therapeutics by 4.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 297,880 shares of the company's stock valued at $566,000 after acquiring an additional 11,689 shares during the period. Finally, Strs Ohio bought a new position in shares of Compass Therapeutics during the 1st quarter valued at approximately $34,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.